A73025

has heparin-like activity

Also Known As:

A 73025; A-73025; Adequan; PSGAG; glycosaminoglycan polysulfate; glycosaminoglycan polysulfuric acid ester; glycosaminoglycan polysulphate; polysulfated glycosaminoglycan; sulfated glycosaminoglycan

Networked: 142 relevant articles (6 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Polysaccharides: 15383
  - Glycosaminoglycans: 5640
    - A73025: 142

Experts

1.	Frisbie, David D: 3 articles (06/2011 - 02/2009)
2.	McIlwraith, C Wayne: 3 articles (06/2011 - 02/2009)
3.	Manfredi, Jane: 2 articles (09/2021 - 08/2021)
4.	Tomlinson, Julia: 2 articles (09/2021 - 08/2021)
5.	Varcoe, Gabriella: 2 articles (09/2021 - 08/2021)
6.	Karousou, Evgenia: 2 articles (12/2020 - 10/2009)
7.	Passi, Alberto: 2 articles (12/2020 - 10/2009)
8.	Feng, Ganjun: 2 articles (08/2014 - 03/2011)
9.	Liu, Hao: 2 articles (08/2014 - 03/2011)
10.	Kawcak, Chris E: 2 articles (06/2011 - 02/2009)

Related Diseases

1.	Osteoarthritis 10/01/1989 - "Therapeutic treatment of canine osteoarthritis with glycosaminoglycan polysulfuric acid ester." 01/01/2021 - "This study aims to investigate how biochemical composition in subchondral bone (SB) relates to the sulfated glycosaminoglycan (sGAG) content of articular cartilage (AC) in the knee joint of guinea pigs from the early to moderate osteoarthritis (OA). " 08/01/1987 - "[Histopathologic studies modification of genetically fixed arthrosis in C 57 black mice by glycosaminoglycan polysulfate]." 01/01/1983 - "This study indicates that glycosaminoglycan polysulphate may inhibit the development of osteoarthritis." 03/01/2022 - "These results support that Adequan given parenterally at 1 mg/kg can be utilized safely in clinical case management as an adjunctive treatment for osteoarthritis in flamingos and potentially other avian species."
2.	Joint Diseases (Joint Disease) 11/01/1996 - "Use of PSGAG is regarded as moderately effective overall and is considered most useful in the treatment of subacute degenerative joint disease. " 11/01/1996 - "Use of PSGAG was reported to be moderately effective in the treatment of the 4 joint disease conditions. " 05/01/1990 - "Nonetheless, these observations provide direct evidence of a truly chondroprotective role for low molecular weight PSGAG in the treatment of equine degenerative joint disease." 11/01/1996 - "Information was obtained on frequency and route of administration of PSGAG for the treatment of each of 4 forms of degenerative joint disease, the efficacy of PSGAG, and its efficacy compared with that of sodium hyaluronate. " 10/01/1981 - "Arteparon, a polysulfated glycosaminoglycan, has been used in Europe for two decades in the treatment of degeneration joint disease and is currently being tested in this country. "
3.	Pain (Aches) 01/01/1988 - "The glycosaminoglycan polysulphate treatment brought about a significant reduction of pain (p less than 0.01) and improvement of joint mobility (p less than 0.001). " 09/01/2021 - "Most events were considered minor (stomach upset, loose stool, pain at injection site, fear) and did not lead to discontinuation of PSGAG. " 08/09/2021 - "Most events were considered minor (stomach upset, loose stool, pain at injection site, fear) and did not lead to discontinuation of PSGAG. " 06/28/1984 - "Glucosamine had a superior effect, in particular in mild arthritis, achieving an improvement of pain in 90%, while glycosaminoglycan polysulphate was successful in advanced cases. " 11/01/2011 - "In trials of injections of sclerosant, platelet-rich plasma, proteinase, glycosaminoglycan polysulfate, sodium hyaluronate, prolotherapy, and botulinum toxin compared with placebo injection or other therapies, only sodium hyaluronate compared with placebo showed consistently better results in the short and long term in overall improvement and pain reduction of lateral epicondylalgia (1 study). "
4.	Synovitis 11/01/1996 - "Use of PSGAG was considered more effective than sodium hyaluronate for the treatment of subacute degenerative joint disease and less effective for idiopathic joint effusion and acute synovitis. " 04/01/2023 - "Effusion synovitis significantly correlated with matrix metalloproteinase-3 (rho=0.63, p<0.001), matrix metalloproteinase-1 (rho=0.50, p=0.003), and sulfated glycosaminoglycan (rho=0.42, p=0.01). "
5.	Colitis 09/01/2021 - "Hyaluronic acid (HA) is a naturally occurring non-sulfated glycosaminoglycan that has shown epithelium protective effects in experimental colitis recently. "

Related Drugs and Biologics

1.	Hyaluronic Acid (Hyaluronan)
2.	A73025
3.	Arteparon
4.	Glycosaminoglycans
5.	Peptide Hydrolases (Proteases)
6.	Therapeutic Uses
7.	Sodium
8.	Collagenases (Collagenase)
9.	Sclerosing Solutions (Sclerosing Agents)
10.	Potassium

Related Therapies and Procedures

1.	Injections
2.	Therapeutics
3.	Prolotherapy
4.	Viscosupplementation
5.	Intra-Articular Injections